Télécharger NbN C&A sur PC

1. The NbN was developed because it has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it appropriately inform the clinician about neuroscience-based prescribing.

2. This proposed nomenclature aims to reflect the current pharmacology knowledge base and cannot necessarily represent the ultimate scientific truth.

3. The taskforce that assembled this app could have taken the stand that our current knowledge base is not enough to define the exact pharmacological domain or the correct mechanisms of action.

4. • The scope is to include all medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.

5. Efficacy and side effects – Aimed to highlight situations in which a compound has no formal approval for an indication, yet there is evidence to support its use in additional indication(s), for example well supported expert guidelines.

6. • The mission of NbN is to embed our current neuroscience advances in the nomenclature.

7. 4 clinically relevant dimensions are also included: 1.Approved indications – Based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) for this age group.

8. “Practical notes” – Summarizes the clinical knowledge that has been "filtered" though the taskforce "sieve".

9. The assumption that children are developing and therefore developmental aspects (e.g. liver and kidney function, brain developmental stage) must be considered in use and dosage.

10. However, as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion.

11. Along these lines, we have come up with a nomenclature that is driven by: pharmacology and mode of action.